Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698000 | 0.82 | DGAT1 (0.54) | NAPRTDGAT1EGFRRAB9ASMN1; SMN2 | |
| SCHEMBL14214692 | 0.82 | DGAT1 (0.50) | NAPRTDGAT1EGFRRAB9ASMN1; SMN2 | |
| SCHEMBL2275746 | 0.79 | DGAT1 (0.51) | NAPRTDGAT1EGFRRAB9ASMN1; SMN2 | |
| SCHEMBL5491825 | 0.78 | DGAT1 (0.54) | NAPRTDGAT1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL14061762 | 0.78 | HDAC1 (0.36) | DGAT1EGFR | |
| SCHEMBL1725915 | 0.78 | HDAC1 (0.36) | DGAT1 | |
| SCHEMBL16697981 | 0.77 | NPC1 (0.56) | DGAT1RAB9AL3MBTL1NPC1MEN1 | |
| SCHEMBL312493 | 0.76 | HDAC1 (0.61) | SMN1; SMN2GAA | |
| SCHEMBL14993009 | 0.76 | KCNQ3 (0.38) | IDO1KCNQ3KCNQ2 | |
| SCHEMBL641282 | 0.76 | HDAC1 (0.61) | DGAT1RAB9ASMN1; SMN2KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338236-B2 | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-06-24 | — | — | US | disclosed |
| US-20250101014-A1 | BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-03-27 | — | — | US | disclosed |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022035805-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-9359329-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2016-06-07 | — | — | US | disclosed |
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2974727-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9186407-B2 | Pharmaceutical compositions and their methods of use | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
| US-20040122015-A1 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004050018-A2 | DICATIONIC 2,5-DIARYLFURAN AZA-ANALOGS AS ANTI-PROTOZOAN AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| EP-1373264-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002079200-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101014-A1 | BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS | GABRA5, GABBR1, GABRA2 | NAPRT 1041/4885DGAT1 1833/4885EGFR 2532/4885 |
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | NAPRT 1001/4885DGAT1 3924/4885EGFR 4025/4885 |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP1, USP18 | NAPRT 3894/4885DGAT1 3627/4885EGFR 1714/4885 |
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NR3C1, NR5A2 | NAPRT 717/4885DGAT1 3870/4885EGFR 249/4885 |
| US-20040122015-A1 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | NR0B1, NR2C2, DECR1 | NAPRT 2912/4885DGAT1 1389/4885EGFR 3845/4885 |
| US-12338236-B2 | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders | GABRA5, GABBR1, GABRA2 | NAPRT 1041/4885DGAT1 1833/4885EGFR 2532/4885 |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | NAPRT 280/4885DGAT1 3302/4885EGFR 1780/4885 |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, CYP2F1, CYP7A1 | NAPRT 362/4885DGAT1 2296/4885EGFR 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.